Fol. Biol. 2011, 57, 200-205
https://doi.org/10.14712/fb2011057050200
Mitoxantrone in Combination with a DNA-PK Inhibitor: Possible Therapy of Promyelocytic Leukaemia Resistant Forms
References
1. , W. M., Jiang, X., Shi, G., Wang, H., Paulson, D. (2009) Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. J. Clin. Invest. 119, 1974-1985.
<https://doi.org/10.1172/JCI33816>
2. , I., Muller, C., Bonnet, J., Favre, G., Cohen-Jonathan, E., Salles, B., Toulas, C. (2002) The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit. Oncogene 21, 6471-6479.
<https://doi.org/10.1038/sj.onc.1205838>
3. , S., Lukas, C., Kitagawa, R., Melander, F., Kastan, M. B., Bartek, J., Lukas, J. (2006) Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J. Cell Biol. 173, 195-206.
<https://doi.org/10.1083/jcb.200510130>
4. , M. S., Reinicke, K. E., Dong, Y., Bey, E. A., Boothman, D. A. (2007) Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, β-lapachone. Cancer Res. 67, 6936-6945.
<https://doi.org/10.1158/0008-5472.CAN-07-0935>
5. , C., Bae, J. H., Kim, M. J., Hwang, J. Y., Kim, S. J., Yoon, M. S., Lee, M. K., Kim, D. W., Chung, B. S., Kang, C. D., Kim, S. H. (2005) Radiosensitization by targeting radioresistance-related genes with protein kinase A inhibitor in radioresistant cancer cells. Exp. Mol. Med. 37, 608-618.
<https://doi.org/10.1038/emm.2005.74>
6. , D. C., Gieseler, F. (2007) Repair of idarubicin-induced DNA damage: a cause of resistance? DNA Repair (Amst) 6, 1618-1628.
<https://doi.org/10.1016/j.dnarep.2007.05.007>
7. , B., Sampath, D., Plunkett, W. (2008) ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res. 68, 7947-7955.
<https://doi.org/10.1158/0008-5472.CAN-08-0971>
8. , J., Coates, J., Jackson, S. P. (2005) Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434, 605-611.
<https://doi.org/10.1038/nature03442>
9. , W. G., Slade, D. L., Dalton, W. S., Meltzer, P. S., Trent, J. M. (1989) Multidrug resistance in mitoxantroneselected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49, 4542-4549.
10. , W. G., Slade, D. L., Parr, R. L., Feldhoff, P. W., Sullivan, D. M., Holguin, M. H. (1995) Alterations in the topoisomerase II α gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II β enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 55, 1707-1716.
11. T., Sueoka-Aragane N., Sato A., Tomimasu R., Ide M., Kurimasa A., Okamoto K., Kimura S., Sueoka E. (2011) NK314 potentiates anti-tumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{α} and DNA-dependent protein kinase. Blood 117, 3575-3584.
<https://doi.org/10.1182/blood-2010-02-270439>
12. , M. J., Kim, H. B., Bae, J. H., Lee, J. W., Park, S. J., Kim, D. W., Park, S. I., Kang, C. D., Kim, S. H. (2009) Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. Biochem. Pharmacol. 78, 573-582.
<https://doi.org/10.1016/j.bcp.2009.05.016>
13. Klener, P. (1996) Anti-cancer Chemotherapy. Galén, Praha (In Czech) (ISBN 80-85824-36-1)
14. , P., Baus, F., Piette, J. (2001) Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193. Oncogene 20, 1990-1999.
<https://doi.org/10.1038/sj.onc.1204262>
15. , H., Schultz, M., Kruh, G. D., Tew, K. D. (1998) Increased expression of DNA-dependent protein kinase confers resistance to adriamycin. Biochim. Biophys. Acta 1381, 131-138.
<https://doi.org/10.1016/S0304-4165(98)00020-8>
16. , S. J., Curtin, N. J., Richardson, C. J., Smith, G. C., Durkacz, B. W. (2003) Radio-sensitization and DNA repair inhibition by the combined use of novel inhibitors of DNAdependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 63, 6008-6015.
